Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

NativeMed vs WeightRx

NativeMed
Graded #184

Lower grade

vs+5.599999999999994
WeightRx
Graded #85

Higher grade

The verdict

WeightRx takes it — 72.1/100 to 66.5/100.

WeightRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. WeightRx is a telehealth provider publishing compounded semaglutide at $250/mo and compounded tirzepatide at $83/mo.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueWeightRx +17
74
91
Dose & formulationEven
64
64
Clinical oversightWeightRx +8
74
82
Labs & monitoringEven
53
53
FulfillmentNativeMed +2
67
65
Contract termsEven
55
55
NativeMed · left barWeightRx · right bar

The numbers

MetricNativeMedWeightRx
WeighScore66.5/10072.1/100
GradeCC
Scorecard rank#184#85
Semaglutide$149/mo (promotional rate, compounded)$250/mo (compounded)
Tirzepatide$183/mo (promotional rate, compounded)$83/mo (term not published, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
NativeMed

Graded #184 · C

Strengths

  • LegitScript Certified (verifiable in the footer)
  • Promotional pricing shown publicly: $149/mo semaglutide, $183/mo tirzepatide
  • Online questionnaire intake, with a live visit added when state law requires it

Where it loses points

  • Pharmacy partners aren't named — described only as 'USA-based' or 'accredited' pharmacies
  • States served aren't listed publicly
  • Prices are promotional — confirm whether they hold past month one or rise to the $299/$399 regular rate
WeightRx

Graded #85 · C

Strengths

  • The tirzepatide figure is published up front, and it is genuinely low against the field
  • Both molecules are offered
  • No membership charge is advertised alongside the medication rate

Where it loses points

  • The $83 monthly rate is advertised as '$83/month ($997/year)', which is twelve months of it — no month-to-month rate is separately published, and the terms state that a rate is locked for its full term
  • Both product pages linked from the homepage return 404, so the plan terms cannot be read before intake
  • Six- and twelve-month plans are non-refundable, and eligible refunds carry a 5% processing fee
  • No dose strength is published anywhere, so what the $83 buys is not stated
  • The named operator is Twist G Marketing, LLC rather than a clinical entity, and the terms carry a binding arbitration and class-action waiver

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard